Evolus, Inc.
NASDAQ:EOLSDrug Manufacturers - Specialty & Generic
-$0.14 today
- Market cap
- $467.95M
- Beta
- 1.33
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.67
Volume 0.80M
Average 0.86M
EOLS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Evolus, Inc.NASDAQ: EOLS
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $2.15M, compared with -$823K a year earlier. Trailing-twelve-month accounts receivables was -$8.53M. Over 3 fiscal years it compounded at +7.0% a year.
Context
- Accounts receivables amounted to 3.9% of revenue in FY2025, down 3.5 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near $2.15M or moves back toward the trailing-twelve-month quarterly average of -$2.13M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (11.51M) USD
- Year-over-year change
- +41.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.51M) | +41.3% |
| FY2024 | 2024-12-31 | (19.6M) | -105.9% |
| FY2023 | 2023-12-31 | (9.52M) | -1.4% |
| FY2022 | 2022-12-31 | (9.39M) | -68.7% |
| FY2021 | 2021-12-31 | (5.57M) | — |
Accounts Receivables vs competitors
How EOLS compares with its peers on the latest reported figures
No competitor Accounts Receivables figures are available to compare.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.81M) | (74.41M) | (61.69M) | (50.42M) | (51.64M) |
| Depreciation & Amortization | 6.31M | 4.5M | 5.87M | 6.02M | 8.74M |
| Deferred Income Tax | 15K | (18K) | 5K | (21K) | 21K |
| Stock-Based Compensation | 9.58M | 10.83M | 16.46M | 22.25M | 20.7M |
| Change in Working Capital | (11.54M) | (34.25M) | (5.9M) | (6.6M) | (22.48M) |
| Accounts Receivables | (5.57M) | (9.39M) | (9.52M) | (19.6M) | (11.51M) |
| Inventory | (2.98M) | (10.69M) | 4.19M | 3.25M | (11.12M) |
| Accounts Payables | (787K) | 968K | (1.02M) | 391K | 10.1M |
| Other Working Capital | (2.21M) | (15.14M) | 450K | 9.36M | (9.95M) |
| Other Non-Cash Items | 9.06M | 8.44M | 11.24M | 10.77M | 2.39M |
| Operating Cash Flow | (33.39M) | (84.91M) | (34.01M) | (18M) | (42.27M) |
| Capital Expenditures | (970K) | (2.94M) | (1.63M) | (1.47M) | (3.44M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 5M | 0 | 0 | 0 | 0 |
| Other Investing Activities | (577K) | (1.32M) | (1.15M) | (3.35M) | 0 |
| Investing Cash Flow | 4.03M | (2.94M) | (1.63M) | (4.82M) | (8.45M) |
| Debt Repayment | (24.37M) | 0 | 50M | 0 | (15K) |
| Common Stock Issued | 103.34M | 0 | 0 | 51.21M | 1.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.92M) | (4.15M) | (5.36M) | (3.8M) | 16.19M |
| Financing Cash Flow | 73.05M | (4.15M) | 44.64M | 47.41M | 17.34M |
| Effect of Forex Changes | (1) | (337K) | (90K) | (478K) | 254K |
| Net Change in Cash | 43.69M | (92.33M) | 8.92M | 24.11M | (33.13M) |
| Free Cash Flow | (34.36M) | (87.85M) | (35.64M) | (19.47M) | (45.71M) |
Evolus, Inc.
NASDAQ:EOLS
Intrinsic Alpha fair value
Locked
Current Price
$7.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.